文献速递血栓与止血

COVID-19住院患者出院后血栓栓塞结局与死亡率:CORE-19注册研究

Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry.
PubMed 文献 · Blood · 2021-01-01

CORE-19前瞻性注册研究纳入2020年3-5月多院区连续住院的COVID-19患者4906例,随访出院后90天。出院后静脉血栓栓塞(VTE)率1.55%、动脉血栓栓塞(ATE)率1.71%、全因死亡率4.83%,复合终点7.13%;出院后抗凝与复合终点风险降低相关(OR 0.54)。

要点

  • COVID-19住院患者出院后90天内VTE、ATE及全因死亡仍较常见。
  • 高龄、既往VTE、ICU停留、CKD、IMPROVE-DD评分≥4等增加出院后血栓栓塞风险。
  • 出院后抗凝治疗与复合终点风险降低46%相关。

核心结论

  • COVID-19住院患者出院后VTE、ATE及全因死亡发生频繁,高龄、心血管危险因素、CKD、IMPROVE-DD评分≥4及ICU停留增加风险。
  • 出院后抗凝治疗与复合终点风险降低46%相关(OR 0.54;95% CI 0.47-0.81)。

研究设计与样本

  • 前瞻性注册研究,纳入2020年3月1日至5月31日多院区连续住院的COVID-19患者4906例,平均年龄61.7岁,男性53.7%。

主要发现

  • 出院后VTE率1.55%,ATE率1.71%,全因死亡率4.83%,大出血率1.73%,复合主要终点率7.13%。
  • 复合终点与高龄(OR 3.66;95% CI 2.84-4.71)、既往VTE(OR 2.99;95% CI 2.00-4.47)、ICU停留(OR 2.22;95% CI 1.78-2.93)、CKD(OR 2.10;95% CI 1.47-3.0)、外周动脉疾病(OR 2.04;95% CI 1.10-3.80)、颈动脉闭塞性疾病(OR 2.02;95% CI 1.30-3.14)、IMPROVE-DD VTE评分≥4(OR 1.51;95% CI 1.06-2.14)及冠心病(OR 1.50;95% CI 1.04-2.17)显著相关。
  • 出院后抗凝与复合终点风险降低显著相关(OR 0.54;95% CI 0.47-0.81)。

关键数值与推荐

  • 出院后VTE率1.55%,ATE率1.71%,全因死亡率4.83%,大出血率1.73%,复合主要终点率7.13%。
  • 出院后抗凝治疗率13.2%。
  • 风险因素包括高龄、既往VTE、ICU停留、CKD、外周动脉疾病、颈动脉闭塞性疾病、IMPROVE-DD VTE评分≥4、冠心病。

临床怎么用

  • 对COVID-19出院患者应评估VTE和ATE风险,尤其高龄、既往VTE、ICU停留、CKD、IMPROVE-DD评分≥4及心血管危险因素者。
  • 出院后抗凝可能降低血栓栓塞和死亡复合风险,但需权衡出血风险。

局限性

  • 观察性注册研究,抗凝治疗为非随机分配,可能存在残余混杂。
  • 研究期间为2020年早期,结论外推至当前变异株和诊疗背景需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Thromboembolic events, including venous thromboembolism (VTE) and arterial thromboembolism (ATE), and mortality from subclinical thrombotic events occur frequently in coronavirus disease 2019 (COVID-19) inpatients. Whether the risk extends postdischarge has been controversial. Our prospective registry included consecutive patients with COVID-19 hospitalized within our multihospital system from 1 March to 31 May 2020. We captured demographics, comorbidities, laboratory parameters, medications, postdischarge thromboprophylaxis, and 90-day outcomes. Data from electronic health records, health informatics exchange, radiology database, and telephonic follow-up were merged. Primary outcome was a composite of adjudicated VTE, ATE, and all-cause mortality (ACM). Principal safety outcome was major bleeding (MB). Among 4906 patients (53.7% male), mean age was 61.7 years. Comorbidities included hypertension (38.6%), diabetes (25.1%), obesity (18.9%), and cancer history (13.1%). Postdischarge thromboprophylaxis was prescribed in 13.2%. VTE rate was 1.55%; ATE, 1.71%; ΑCM, 4.83%; and MB, 1.73%. Composite primary outcome rate was 7.13% and significantly associated with advanced age (odds ratio [OR], 3.66; 95% CI, 2.84-4.71), prior VTE (OR, 2.99; 95% CI, 2.00-4.47), intensive care unit (ICU) stay (OR, 2.22; 95% CI, 1.78-2.93), chronic kidney disease (CKD; OR, 2.10; 95% CI, 1.47-3.0), peripheral arterial disease (OR, 2.04; 95% CI, 1.10-3.80), carotid occlusive disease (OR, 2.02; 95% CI, 1.30-3.14), IMPROVE-DD VTE score ≥4 (OR, 1.51; 95% CI, 1.06-2.14), and coronary artery disease (OR, 1.50; 95% CI, 1.04-2.17). Postdischarge anticoagulation was significantly associated with reduction in primary outcome (OR, 0.54; 95% CI, 0.47-0.81). Postdischarge VTE, ATE, and ACM occurred frequently after COVID-19 hospitalization. Advanced age, cardiovascular risk factors, CKD, IMPROVE-DD VTE score ≥4, and ICU stay increased risk. Postdischarge anticoagulation reduced risk by 46%.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Giannis D, Allen SL, Tsang J, et al. Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry. Blood. 2021. PMID: 33824972. doi:10.1182/blood.2020010529

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。